{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:25:27Z","timestamp":1792106727377,"version":"4.4.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2018,6,26]]},"DOI":"10.1001\/jama.2018.8194","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T18:32:40Z","timestamp":1530037960000},"page":"2507","source":"Crossref","is-referenced-by-count":52,"title":["Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy"],"prefix":"10.1001","volume":"319","author":[{"given":"Vanessa","family":"Selak","sequence":"first","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kerr","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"},{"name":"Middlemore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Poppe","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Wu","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matire","family":"Harwood","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"},{"name":"Te Kupenga Hauora M\u0101ori, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Grey","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Jackson","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Wells","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"16","key":"joi180068r1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.116.022134","article-title":"Moving toward the next paradigm for cardiovascular prevention.","volume":"133","author":"Robinson","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"joi180068r2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force.","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"joi180068r3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am J Med"},{"issue":"9678","key":"joi180068r4","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"25","key":"joi180068r5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"1 pt 2","key":"joi180068r6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles.","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"issue":"11","key":"joi180068r7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project.","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"issue":"7659","key":"joi180068r8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"joi180068r9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement.","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"issue":"12","key":"joi180068r10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M15-2129","article-title":"Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the US Preventive Services Task Force.","volume":"164","author":"Dehmer","year":"2016","journal-title":"Ann Intern Med"},{"issue":"21","key":"joi180068r11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes.","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"issue":"6999","key":"joi180068r12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/bmj.311.6999.222","article-title":"Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom.","volume":"311","author":"Rockall","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"joi180068r13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"joi180068r15","first-page":"22","article-title":"Cohort profile: the PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19).","volume":"46","author":"Wells","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1437","key":"joi180068r22","first-page":"27","article-title":"Incidence and type of bleeding complications early and late after acute coronary syndrome admission in a New Zealand cohort (ANZACS-QI-7).","volume":"129","author":"Voss","year":"2016","journal-title":"N Z Med J"},{"key":"joi180068r23","doi-asserted-by":"publisher","first-page":"g4606","DOI":"10.1136\/bmj.g4606","article-title":"Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.","volume":"349","author":"Hippisley-Cox","year":"2014","journal-title":"BMJ"},{"key":"joi180068r24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ijcard.2015.11.067","article-title":"\u201cReal-world\u201d haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand.","volume":"203","author":"Nishtala","year":"2016","journal-title":"Int J Cardiol"},{"key":"joi180068r25","first-page":"23","article-title":"Natural history of bleeding and characteristics of early bleeders among warfarin initiators\u2014a cohort study in Finland.","volume":"8","author":"Rikala","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"10133","key":"joi180068r26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/S0140-6736(18)30664-0","article-title":"Cardiovascular disease risk prediction equations in 400?000 primary care patients in New Zealand: a derivation and validation study.","volume":"391","author":"Pylypchuk","year":"2018","journal-title":"Lancet"},{"issue":"1435","key":"joi180068r27","first-page":"21","article-title":"Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.","volume":"129","author":"Selak","year":"2016","journal-title":"N Z Med J"},{"issue":"10093","key":"joi180068r28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"joi180068r16","volume-title":"Evidence-Based Best Practice Guideline: The Assessment and Management of Cardiovascular Risk","author":"New Zealand Guidelines Group","year":"2003"},{"key":"joi180068r17","volume-title":"Cardiovascular Disease Risk Assessment: New Zealand Primary Care Handbook 2012","author":"New Zealand Ministry of Health","year":"2013"},{"key":"joi180068r18","volume-title":"National Health Index Data Dictionary Version 5.3","author":"New Zealand Ministry of Health","year":"2009"},{"key":"joi180068r19","volume-title":"Mortality Collection Data Dictionary Version 1.3","author":"New Zealand Ministry of Health","year":"2009"},{"key":"joi180068r20","volume-title":"National Minimum Dataset (Hospital Inpatient Events) Data Mart Data Dictionary Version 7.8","author":"New Zealand Ministry of Health","year":"2016"},{"key":"joi180068r21","volume-title":"Pharmaceutical Claims Data Mart (PHARMS) Data Dictionary Version 4.1","author":"New Zealand Ministry of Health","year":"2012"},{"key":"joi180068r14","unstructured":"Aspirin in Reducing Events in the Elderly protocol. Version 9. November 2014. https:\/\/aspree.org\/aus\/wp-content\/uploads\/sites\/2\/2014\/04\/ASPREE-Protocol-AUS-Version-9-Nov-2014-Monash-approved.pdf. Accessed June 6, 2018."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2685989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T18:32:49Z","timestamp":1530037969000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2018.8194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6,26]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2018.8194","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}